Structure of a pseudokinase domain switch that controls oncogenic activation of Jak kinases by Toms, Angela V. et al.
 Structure of a pseudokinase domain switch that controls oncogenic
activation of Jak kinases
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Toms, A. V., A. Deshpande, R. McNally, Y. Jeong, J. M. Rogers,
C. U. Kim, S. M. Gruner, et al. 2013. “Structure of a pseudokinase
domain switch that controls oncogenic activation of Jak kinases.”
Nature structural & molecular biology 20 (10):
10.1038/nsmb.2673. doi:10.1038/nsmb.2673.
http://dx.doi.org/10.1038/nsmb.2673.
Published Version doi:10.1038/nsmb.2673
Accessed February 19, 2015 3:50:42 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12152821
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Structure of a pseudokinase domain switch that controls
oncogenic activation of Jak kinases
Angela V. Toms1,2, Anagha Deshpande3,4, Randall McNally1,2, Youngjee Jeong1, Julia M.
Rogers2,5, Chae Un Kim6, Sol M. Gruner6,7, Scott B. Ficarro1,2,8, Jarrod A. Marto1,2,8, Martin
Sattler3,4, James D. Griffin3,4, and Michael J. Eck1,2
1Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School,
Boston, MA
2Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA
3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
4Department of Medicine, Harvard Medical School, Boston, MA
5Committee on Higher Degrees in Biophysics, Harvard University, Cambridge, MA
6Cornell High Energy Synchrotron Source, Cornell University, Ithaca, New York
7Physics Department, Cornell University, Ithaca, New York
8Blais Proteomics Center, Dana-Farber Cancer Institute, Boston, MA
Abstract
The V617F mutation in the Jak2 pseudokinase domain causes myeloproliferative neoplasms, and
the equivalent mutation in Jak1 (V658F) is found in T-cell leukemias. Crystal structures of wild
type and V658F mutant human Jak1 pseudokinase reveal a conformational switch that remodels a
linker segment encoded by exon 12, which is also a site of mutations in Jak2. This switch is
required for V617F-mediated Jak2 activation, and possibly for physiologic Jak activation.
The receptors for diverse cytokines, including erythropoietin (EPO), growth hormone,
interleukins and interferons, initiate intracellular signaling via one or more members of the
Jak family of non-receptor tyrosine kinases1,2. Jak kinases contain a FERM domain, an
SH2-like domain, and a pseudokinase domain (also referred to as the Jak homology 2, or
JH2 domain) adjacent to their C-terminal tyrosine kinase domain (Fig. 1a). The
pseudokinase domain has a protein kinase fold, but key catalytic residues are not conserved
and the domain is thought to inhibit the adjacent tyrosine kinase domain, perhaps via an
intramolecular interaction3. Somatic gain-of-function mutations in Jaks underlie a number of
hematologic malignancies4, and the pseudokinase domain is the most frequent site of these
activating mutations5. In particular, the V617F mutation in the Jak2 pseudokinase is found
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in ∼95% of patients with polycythemia vera (PV)6-9, a myeloproliferative neoplasm (MPN)
characterized by EPO-independent overproduction of red blood cells due to constitutive
signaling from Jak2 V617F in complex with the erythropoietin receptor (EPO-R)10. The
corresponding mutation in Jak1 (V658F) has been identified in T-cell acute lymphoblastic
leukemia11 and also leads to constitutive catalytic activation12. A subset of PV patients who
are V617F-negative have mutations in exon 12 of Jak213,14, which encodes a portion of the
polypeptide chain that links the SH2-like and pseudokinase domains (SH2-PK linker).
To better understand the pseudokinase domain and the effects of pathogenic mutations, we
determined crystal structures of a wild type and V658F mutant fragment of human Jak1
spanning the pseudokinase domain and a segment of the SH2-PK linker (residues 561-852).
The wild type and mutant structures were refined at resolutions of 1.8Å and 1.9Å,
respectively (see Supplementary Table 1 and Methods online). The overall architecture of
the pseudokinase domain closely resembles that of typical tyrosine kinases, with an N-
terminal lobe composed of five β-strands and the C-helix, and a larger C-terminal lobe (Fig.
1b). Several features of the pseudokinase domain appear to be inconsistent with
phosphotransfer activity. In particular, the region corresponding to the kinase activation loop
adopts a well-defined conformation that is expected to preclude binding of polypeptide
substrates (Supplementary Fig. 1). At the N-terminus of the domain, the SH2-PK linker
adopts a partially α-helical conformation and extends across the N-lobe, roughly
perpendicular to the C-helix. The Jak1 domain superimposes well with a recently reported
structure of the Jak2 pseudokinase15 (RMSD 1.26 Å for 261 equivalent residues, Fig. 1c),
but the Jak2 structure lacks the SH2-PK linker, which was truncated in the crystallized
construct.
Val658 lies within the N-lobe of the domain, at the end of strand β4. In the V658F mutant,
the β4-β5 loop folds inward toward the C-helix, and the mutant Phe658 packs in an edge-to-
face manner with Phe636 in the C-helix (Fig. 2a). Strikingly, the phenyl ring of Phe658
occupies precisely the same position occupied by that of Phe575 in the wild type structure.
Phe575 lies in the SH2-PK linker, and the V658F mutation induces a coordinated
rearrangement of this segment. In the mutant, Phe575 is shifted by ∼10Å and becomes
solvent-exposed. Both the V658F and wild type crystals contain two molecules in the
asymmetric unit, and interestingly, we observe essentially the same rearrangement in
molecule “B” in the wild type structure that we observe in the V658F mutant, demonstrating
that the wild type pseudokinase domain can also adopt the Phe575-flipped conformation
(Fig. 2b). In the V658F mutant structure, both the A and B molecules adopt the “flipped”
conformation with Phe575 exposed. The electron density for the linker segments is clear and
continuous in both the wild type and V658F structures (Supplementary Fig. 2a, b).
Three residues appear to be centrally important for the observed rearrangement; Phe575 in
the SH2-PK linker, Phe636 in the C-helix, and V658F, the site of the MPN mutation
(V617F-site). We refer to these three residues as the F-F-V triad. This triad is highly
conserved in Jak-family kinases, and these residues appear to be evolutionarily “coupled”;
that is, substitutions in one position are almost invariably accompanied by changes in one of
the other residues in the triad (Supplementary file ConSurf_Alignment.pdf). Interestingly,
human Jak3 has a methionine at the V617F-site, and is the only human Jak kinase that is not
activated by phenylalanine mutations at this site12. This pattern of conservation of residues
comprising the F-F-V triad, combined with our observation that the wild type pseudokinase
domain can also adopt the flipped conformation, leads us to speculate that the observed
rearrangement is part of a structural switch controlling catalytic activation both in wild type
Jak kinases and in the context of the V617F-site mutation. Consistent with a model in which
the mutation promotes a rearrangement related to that induced by cytokine, cells bearing
Jak2 V617F are hyper-responsive to EPO and even absent EPO stimulation, they proliferate
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at a rate equivalent to cells bearing wild type Jak2 with cytokine stimulation8. In contrast,
pseudokinase domain deletions result in constitutive but diminished catalytic activation, and
deletion mutants are not further stimulated by cytokine3.
To examine the requirement for the observed phenylalanine-flip rearrangement in Jak
activation, we introduced point mutations in the SH2-PK linker and F-F-V triad and tested
their effect on the ability of the V617F mutation in Jak2 to promote IL-3 independent
growth of Ba/F3 cells. We carried out this structure-function analysis in Jak2 because of the
availability of the well-characterized Ba/F3 cell system (Ba/F3.EPO-R) in which the EPO
receptor is co-expressed with mutant Jak2 to allow its proper folding and maturation16. In
the SH2-PK linker, mutation of the flipped phenylalanine (Phe537 in Jak2) to either valine
or alanine abrogated V617F-driven proliferation (Fig. 2c, Supplementary Fig. 3). Residue
Leu573 forms hydrophobic interactions that appear to stabilize the helical segment of the
SH2-PK linker, and mutation of the corresponding residue in Jak2 from methionine to
alanine (M535A) also reversed V617F-driven proliferation. In contrast, a conservative
M535F substitution at this position was without effect (Fig. 2c). Phe636 in the C-helix forms
the platform for the observed rearrangement, and we found that mutation of the
corresponding residue in Jak2 (Phe595) to alanine also abrogated the transforming effect of
V617F (Fig. 2c), as previously observed17,18. The V615F mutation in Jak2 modestly
enhanced proliferation as compared with V617F alone, consistent with a role in promoting
the SH2-PK linker rearrangement, but was not activating on its own (Fig. 2c and
Supplementary Fig. 4f). Collectively, the effects of these mutations support a role for the
phenylalanine-flip rearrangement in V617F-driven Jak2 activation. Analysis of these
mutations in the context of wild type Jak2 reconstituted in Jak2-deficient cells will be
required to establish whether the rearrangement is also required for EPO-driven activation of
Jak2.
We also probed a crystal packing interaction between the two molecules in the asymmetric
unit. This non-crystallographic dimer buries a large surface area (∼2080 Å2) and involves
both V658F and Phe575 in the SH2-PK linker, but we found no role for this interface in Jak
regulation (Supplementary Fig. 4).
Somatic gain of function mutations in exon 12 of Jak2 map to the SH2-PK linker, and an
activating mutation in Jak3 is also found in this region (Fig. 2d). These alterations are
expected to disrupt the observed conformation of the linker and may promote repositioning
of the β4-β5 loop as we observe in the Jak1 V658F mutant (Supplementary Fig. 2c, d). Such
a shift in the β4-β5 loop would in turn require rearrangement of the linker segment.
Interestingly, an in vitro screen with Jak2 identified similar activating point mutations in the
SH2-PK linker, leading to the conclusion that the SH2-PK linker is critical for mediating
autoinhibition and cytokine-induced activation of Jak219.
While this manuscript was under review, a structure of the wild type Tyk2 pseudokinase
domain was released in the Protein Data Bank (PDB ID 3ZON). The Tyk2 structure does
include the SH2-PK linker and is very similar overall to the wild type Jak1 structure
described here (RMSD 1.15Å for 258 aligned residues), however the linker conformation
differs in detail (Supplementary Fig. 5). In Tyk2, the linker takes a similar path across the N-
lobe, but does not adopt a helical conformation. Despite this difference, Phe581 (the
equivalent of Phe575 in Jak1) is also in contact with the phenylalanine in the C-helix and
would also be expected to rearrange in the context of the V617F-site mutation. It is unclear
whether the difference in linker conformation represents a genuine difference between Jak1
and Tyk2, or whether it may arise from crystal packing interactions in this region in one or
both structures.
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In the Jak2 pseudokinase domain, stabilization of the C-helix is proposed to mediate in part
the activating effect of the V617F mutation15. The C-helix is three residues longer at its N-
terminus in the V617F mutant, and a break in regular hydrogen bonding near the center of
the helix is also “repaired” in the V617F structure. This break in the C-helix appears to be
unique to the Jak2 wild type structure, as the C-helix is continuous in all of our Jak1
structures and in Tyk2. However, we do observe a corresponding difference in the length of
the C-helix in molecule “A” as compared with molecule “B” in the Jak1 pseudokinase
structures, irrespective of the presence of the V658F mutation. In the Tyk2 pseudokinase
domain, the longer C-helix is also observed in the wild-type context. Thus this is a
conformationally labile region of the pseudokinase domain, but further work will be
required to understand how alternate conformations of this segment may relate to Jak
regulation.
Despite the lack of conserved active site residues, the Jak2 pseudokinase domain is reported
to have catalytic activity and to autophosphorylate itself on both Ser523 and Tyr57020.
These are autoinhibitory phosphorylation sites, and the V617F mutation has been proposed
to promote Jak2 activation in part by abrogating pseudokinase catalytic activity and
therefore phosphorylation of these sites15,20. The Ser523 and Tyr570 phosphorylation sites
are not conserved in Jak1 or other family members, and we do not observe
autophosphorylation of the Jak1 pseudokinase domain at alternate sites (Supplementary Fig.
6). Furthermore, the pseudokinase activation loop in Jak1 and Jak2, in both wild type and
V617F-site mutants, adopts a conformation that blocks the expected position of a
phosphoacceptor (Supplementary Fig. 1e). While we do not dismiss the possibility that
catalytic activity of the pseudokinase domain plays a role in regulation of Jak2 and perhaps
other family members, we favor a model in which the V617F mutation promotes activation
primarily via rearrangement of the pseudokinase domain and SH2-PK linker, as described
here. The F-F-V triad, which is central to this rearrangement, is highly conserved among all
Jak kinases. Furthermore, this model provides a unifying explanation for the activating
effects of both the V617F and exon 12 mutations in myeloproliferative disorders.
An obvious outstanding question is how the rearrangement we observe here leads to
activation of the adjacent tyrosine kinase domain. The remodeled surface of the linker/
pseudokinase unit could destabilize autoinhibitory interactions within the intact Jak kinase
and also potentially promote activation by favoring dimerization or via intramolecular
interaction with the kinase domain proper. Structural studies of longer fragments of Jak
including at a minimum both the pseudokinase and kinase domains will be required to
definitively address this question at a structural level.
Online Methods
Protein expression and purification
Constructs spanning residues 561-852 of human Jak1 bearing the wild-type sequence or
V658F mutation were subcloned into a modified pTriEx vector (Novagen) for expression as
N-terminal 6xHis plus glutathione-S-transferase (GST) fusion proteins with a tobacco etch
virus (TEV) protease recognition sequence. The recombinant baculoviruses were generated
using the BacVector3000 system (Invitrogen) and subsequently plaque purified. For
induction of protein expression the BIICs/TIPS method was used21. Hi5 cells were cultured
in shaker flasks using Express Five serum free medium and at a cell density of ∼1.4 million/
mL, cultures were infected with recombinant baculovirus. Infection was allowed to proceed
for 60-66 hr to achieve optimal expression of target protein prior to harvest by
centrifugation. The cells were washed once in 20mM Tris pH 8.0, 150 mM NaCl, 5%
glycerol and flash-frozen in liquid nitrogen and stored at −80°C.
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For lysis, cells were thawed, resuspended in lysis buffer (100mM Tris pH8, 300 mM NaCl,
10% glycerol, 5 mM β-mercaptoethanol, 1% Nonidet-P40 and Roche Complete EDTA-free
Protease Inhibitor Cocktail) and incubated on ice for 45 minutes. Cell debris was removed
by centrifugation and the supernatant was incubated for 45 minutes at 4°C with Ni-NTA
agarose (Qiagen). Beads were washed with a step gradient of Ni wash buffer (20 mM Tris
pH 8, 500 mM NaCl, 10% glycerol, 5 mM β-mercaptoethanol and 0.02% CHAPS)
containing 0 mM, 10 mM, 20 mM and 40 mM imidazole and then eluted with elution buffer
(Ni wash buffer with 250 mM imidazole). The eluate was supplemented with 5 mM DTT
and then incubated with glutathione sepharose (GE Healthcare) beads for 2 hours at 4°C.
The beads were washed and protein eluted by GST elution buffer (20 mM Tris pH 8.0, 500
mM NaCl, 10% glycerol, 2.5 mM TCEP, 5 mM glutathione and 0.02% CHAPS). TEV
protease was then added and digestion was carried out at 4°C overnight to remove the
6xHis-GST tag. The digested protein was supplemented with 15 mM imidazole and passed
over a Ni-NTA agarose (Qiagen) column to remove 6xHis-GST tag and 6xHis-tagged TEV
protease. The flow-through was concentrated and run on a Superdex 200 gel filtration
column equilibrated in final buffer (20 mM Tris pH 8.0, 500 mM NaCl, 10% glycerol, 4
mM DTT and 0.02% CHAPS). The eluted peak was concentrated to 4 mg/ml, flash frozen in
liquid nitrogen, and stored at −80°C.
Crystallization and structure determination
Crystals of both the wild type and V658F Jak1 pseudokinase were grown by hanging drop
vapor diffusion at 20°C by mixing equal volumes of protein solution with a well solution
consisting of 1.2 – 1.5 M sodium citrate (pH 6.3-6.6), 6 mM DTT and 0-30 mM NDSB 256.
Prior to data collection crystals were coated in NVH oil and then high-pressure cryocooled22
or directly plunge-frozen in liquid nitrogen. Data for Jak1 WT were collected at CHESS on
beamline A1. Data for Jak1 V658F were collected at the Advanced Photon Source on
beamline 24-C. Diffraction data were processed with the HKL suite of programs23. The
structure was determined by molecular replacement using the C-lobe of focal adhesion
kinase (PDB ID 1MP824 as a search model. The model was fit to the crystallographic data
via manual model building with Coot25 and refinement with CNS26,27 and REFMAC28,29,
and for the Jak1 WT structure was ultimately refined to a crystallographic R-value of 18.2
(Rfree=20.9). Analogous procedures were used to obtain the structure of the V658F mutant.
Mass spectrometry
The Jak1 pseudokinase domain (residues 561-852) was incubated with 300 units/mL calf
intestinal phosphatase (CIP) (New England Biosciences) at 37°C for 30 minutes or 1 mM
ATP/10 mM MgCl2 at 37°C for 30 minutes followed by 300 units/mL CIP at 37°C for 30
minutes. Treated and untreated Jak1 pseudokinase (5 μg) were injected onto a self-packed
reversed phased column (1/32” O.D. × 500 μm I.D. PEEK tubing with 5 cm of POROS
10R2 resin). After desalting, protein was eluted with an HPLC gradient (0-100% B in 1
minute, A=0.2M acetic acid in water, B=0.2 M acetic acid in acetonitrile, flow rate = 10 μL/
min) into an LTQ ion trap mass spectrometer (ThermoFisher Scientific, San Jose, CA). Data
were acquired in profile mode scanning m/z 300-2000. Mass spectra were deconvoluted
using MagTran1.03b2 software30.
Autoradiography
Jak1 pseudokinase at a concentration of 1 mg/mL was incubated at room temperature with 1
μCi [γ-32P]-ATP in a reaction buffer containing 20 mM Tris pH 8.0, 300 mM NaCl, 10%
glycerol, 4 mM DTT, 1 mM ATP, and 10 mM MgCl2 or MnCl2, and quenched with the
addition of 100 mM EDTA. The autophosphorylation of EGFR kinase domain was
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measured under identical conditions as a positive control for detection of phosphorylation.
Phosphorylation was monitored by SDS-PAGE followed by autoradiography.
Analysis of Jak2 mutants in Ba/F3 cells
Structure-function studies of Jak2 mutants in Ba/F3 cells bearing the Epo receptor were
carried out essentially as previously described31. Briefly, point mutations were introduced in
the pMSCV.JAK2V617F expression vector by site-directed mutagenesis using the
QuickChange II XL Mutagenesis Kit (Agilent technologies) and specific primers
constructed. The sequence of the entire mutagenized cDNA was verified by DNA
sequencing. Mouse Ba/F3 cells expressing EPO-R (Ba/F3.EPO-R) were maintained in
RPMI 1640 containing 10% fetal bovine serum and WEHI-3B conditioned medium. Ba/
F3.EPO-R cells were transduced with the mutagenized Jak2 V617F using retroviral
supernatant (293T cell method) by spin infection. Cells were grown for 2 days and sorted for
GFP positive cells. Proliferation was measured by growing cells in 1 mL cultures with or
without IL-3 for three days. The number of viable cells was determined daily using trypan
blue exclusion.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 2.
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